DUBLIN--(BUSINESS WIRE)--The "Psoriatic
Arthritis - Pipeline Review, H2 2017" report has been added to Research
and Markets' offering.
Pharmaceutical and Healthcare
disease pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2017,
provides an overview of the Psoriatic Arthritis (Musculoskeletal
Disorders) pipeline landscape.
Psoriatic arthritis is a form
of arthritis that affects some people who have psoriasis. Symptoms
include swollen fingers and toes, foot pain and lower back pain. Risk
factors include age, family history and psoriasis. Treatment includes
NSAIDs, immunosuppressants and surgery.
Psoriatic Arthritis -
Pipeline Review, H2 2017, provides comprehensive information on the
therapeutics under development for Psoriatic Arthritis (Musculoskeletal
Disorders), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.
The Psoriatic Arthritis
(Musculoskeletal Disorders) pipeline guide also reviews of key players
involved in therapeutic development for Psoriatic Arthritis and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Pre-Registration, Phase III, Phase II, Phase
I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 5, 8,
10, 1, 24, 9 and 3 respectively.
Psoriatic Arthritis
(Musculoskeletal Disorders) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.
Key Topics
Covered:
- Introduction
- Psoriatic Arthritis - Overview
- Psoriatic Arthritis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Psoriatic Arthritis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Psoriatic Arthritis - Companies Involved in Therapeutics Development
- 3SBio Inc
- AbbVie Inc
- AbGenomics International Inc
- Aclaris Therapeutics Inc
- Adello Biologics LLC
- Allergan Plc
- Alteogen Inc
- Amgen Inc
- Biocon Ltd
- Bionovis SA
- Coherus BioSciences Inc
- Eli Lilly and Co
- Formycon AG
- Forward Pharma AS
- Fresenius SE & Co KGaA
- Galapagos NV
- Genor BioPharma Co Ltd
- Immunwork Inc
- Innovent Biologics Inc
- Johnson & Johnson
- KPI Therapeutics Inc
- Morphotek Inc
- Mycenax Biotech Inc
- Nichi-Iko Pharmaceutical Co Ltd
- Novo Nordisk AS
- Nuevolution AB
- Oncobiologics Inc
- Pfizer Inc
- Reliance Life Sciences Pvt Ltd
- Rigel Pharmaceuticals Inc
- Sandoz International GmbH
- Sun Pharma Advanced Research Company Ltd
- SynAct Pharma AB
- UCB SA
- Xbrane Biopharma AB
For more information about this report visit https://www.researchandmarkets.com/research/r9tkwf/psoriatic